Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 2 1

Status

No longer available 4Completed 4Approved for marketing 2

Sponsor Class

INDUSTRY 3FED 1

Study Type

Interventional 4

Sponsor

Conditions

Lambert-Eaton Myasthenic Syndrome 4Rare Diseases 1Neurologic Manifestations 1Myasthenia Gravis 1Mental Disorders 1

Interventions

Amifampridine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Lambert-Eaton Myasthenic Syndrome × Amifampridine × Clear all
NCT02970162 2018-12-24

Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)

Catalyst Pharmaceuticals, Inc.

Phase 3 Completed
26 enrolled 10 charts

Lambert-Eaton Myasthenic Syndrome

NCT01377922 2018-01-04

A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

Catalyst Pharmaceuticals, Inc.

Phase 3 Completed
38 enrolled 12 charts

Lambert-Eaton Myasthenic Syndrome

NCT01511978 2017-07-11

DAPPER

Jacobus Pharmaceutical

Phase 2 Completed
32 enrolled 16 charts

Lambert-Eaton Myasthenic Syndrome

NCT00004832 2015-03-25

Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome

FDA Office of Orphan Products Development

Phase NA Completed
26 enrolled

Mental Disorders, Neurologic Manifestations, Lambert-Eaton Myasthenic Syndrome, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡